U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06827145) titled 'Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC' on Feb. 10.
Brief Summary: This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation
Study Start Date: Oct. 14, 2024
Study Type: INTERVENTIONAL
Condition:
Non-Small-Cell Lung Cancer
Intervention:
DRUG: Vebreltinib
Vebreltinib 100mg oral BID
DRUG: Osimertinib
Osimertinib 80mg oral once daily.
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: National ...